Search Results - "VON DER LEYEN, H"

European survey on national training activities in clinical research by Magnin, A, Iversen, V Cabral, Calvo, G, Čečetková, B, Dale, O, Demlova, R, Blasko, Gy, Keane, F, Kovacs, G L, Levy-Marchal, C, Monteiro, E C, Palmisano, L, Pella, D, Portolés Pérez, A, Rascol, O, Schmid, C, Tay, F, von der Leyen, H, Ohmann, C

“…Investigator-initiated clinical studies (IITs) are crucial to generate reliable evidence that answers questions of day-to-day clinical practice. Many…”
Get full text

Gene Therapy Inhibiting Neointimal Vascular Lesion: In vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene by von der Leyen, Heiko E., Gibbons, Gary H., Morishita, Ryuichi, Lewis, Neil P., Zhang, Lunan, Nakajima, Masatoshi, Kaneda, Yasufumi, Cooke, John P., Dzau, Victor J.

“…It is postulated that vascular disease involves a disturbance in the homeostatic balance of factors regulating vascular tone and structure. Recent developments…”
Get full text

Characteristics of high‐ and low‐risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes by Tofte, N., Lindhardt, M., Adamova, K., Beige, J., Beulens, J. W. J., Birkenfeld, A. L., Currie, G., Delles, C., Dimos, I., Francová, L., Frimodt‐Møller, M., Girman, P., Göke, R., Havrdova, T., Kooy, A., Mischak, H., Navis, G., Nijpels, G., Noutsou, M., Ortiz, A., Parvanova, A., Persson, F., Ruggenenti, P. L., Rutters, F., Rychlík, I., Spasovski, G., Speeckaert, M., Trillini, M., Leyen, H., Rossing, P.

“…Aim To compare clinical baseline data in individuals with Type 2 diabetes and normoalbuminuria, who are at high or low risk of diabetic kidney disease based on…”
Get full text

Molecular profiles as a function of treatment response/progression free survival in a prospective cervical cancer study (RAIDs) by Scholl, S., De Koning, L., Popovic, M., Anne, D.L.R., Floquet, A., Berns, E., Kenter, G., Kereszt, A., Girard, E., von der Leyen, H., Dureau, S., Fourchotte, V., Rouzier, R., Kamal, M., Consortium, R.

Get full text

Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study by Deterding, K, Spinner, C, Schott, E, Welzel, T, Gerken, G, Klinker, H, Spengler, U, Wiegand, J, Schulze zur Wiesch, J, Pathil, A, Cornberg, M, Umgelter, A, Zöllner, C, Zeuzem, S, von der Leyen, H, von Witzendorff, D, Manns, M.P, Wedemeyer, H

Get full text

A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer by von der Leyen, H E, Braun-Dullaeus, R, Mann, M J, Zhang, L, Niebauer, J, Dzau, V J

“…In this study, we report a method of controlled pressure-mediated delivery of "naked" DNA that achieves efficient and safe arterial gene and oligonucleotide…”
Get more information

Expression of inducible nitric oxide synthase in human heart failure by HAYWOOD, G. A, TSAO, P. S, COOKE, J. P, MCKENNA, W. J, FOWLER, M. B, VON DER LEYEN, H. E, MANN, M. J, KEELING, P. J, TRINDADE, P. T, LEWIS, N. P, BYRNE, C. D, RICKENBACHER, P. R, BISHOPRIC, N. H

“…There is increasing evidence that alterations in nitric oxide synthesis are of pathophysiological importance in heart failure. A number of studies have shown…”
Get full text

Cell Cycle Protein Expression in Vascular Smooth Muscle Cells In Vitro and In Vivo Is Regulated Through Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin by Braun-Dullaeus, Ruediger C, Mann, Michael J, Seay, Ulrike, Zhang, Lunan, von der Leyen, Heiko E, Morris, Randall E, Dzau, Victor J

“…Cell cycle progression represents a key event in vascular proliferative diseases, one that depends on an increased rate of protein synthesis. An increase in…”
Get full text

A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy by Braun-Dullaeus, R C, Mann, M J, Ziegler, A, von der Leyen, H E, Dzau, V J

“…Angiotensin II (Ang II) has been shown to stimulate either hypertrophy or hyperplasia. We postulated that the differential response of vascular smooth muscle…”
Get full text

Early detection by urinary proteome analysis : A new concept in patient management of diabetic nephropathy by Beige, J, Drube, J, von der Leyen, H, Pape, L, Rupprecht, H

“…BACKGROUNDThe early detection and treatment of diabetic nephropathy (DN) is of crucial importance as patients with diabetes mellitus represent the largest…”
Get full text

Therapeutic potential of nitric oxide synthase gene manipulation by VON DER LEYEN, Heiko E, DZAU, Victor J

Get full text

Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts by Mann, M J, Gibbons, G H, Tsao, P S, von der Leyen, H E, Cooke, J P, Buitrago, R, Kernoff, R, Dzau, V J

“…We have recently shown that ex vivo gene therapy of rabbit autologous vein grafts with antisense oligodeoxynucleotides (AS ODN) blocking cell cycle regulatory…”
Get full text

12PImpact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs) by Scholl, S, Latouche, A, De Koning, L, Popovic, M, de la Rochefordière, A, Berns, E, Gestraud, P, Girard, E, Lecerf, C, von der Leyen, H, Roman Roman, S, Rouzier, R, Kamal, M, Consortium, R

“…Abstract Background Between 2013 and 2017, the RAIDs consortium conducted a European biobanking study, [BioRAIDs (NCT02428842)] aiming at prospectively…”
Get full text

Impact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs) by Scholl, S., Latouche, A., De Koning, L., Popovic, M., de la Rochefordière, A., Berns, E., Gestraud, P., Girard, E., Lecerf, C., von der Leyen, H., Roman Roman, S., Rouzier, R., Kamal, M., Consortium, R.

Get full text

959PMolecular profiles as a function of treatment response/progression free survival in a prospective cervical cancer study (RAIDs) by Scholl, S, De Koning, L, Popovic, M, Anne, D L R, Floquet, A, Berns, E, Kenter, G, Kereszt, A, Girard, E, von der Leyen, H, Dureau, S, Fourchotte, V, Rouzier, R, Kamal, M, Consortium, R

Get full text

LB08 - Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study by Deterding, K., Spinner, C., Schott, E., Welzel, T., Gerken, G., Klinker, H., Spengler, U., Wiegand, J., Schulze zur Wiesch, J., Pathil, A., Cornberg, M., Umgelter, A., Zöllner, C., Zeuzem, S., von der Leyen, H., von Witzendorff, D., Manns, M.P., Wedemeyer, H.

Get full text

The concept and potentials of cardiovascular gene therapy by Dzau, V J, von der Leyen, H E, Morishita, R

Get full text

DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HVJ)-liposomes by Mann, M J, Morishita, R, Gibbons, G H, von der Leyen, H E, Dzau, V J

“…Manipulation of the genetic machinery of cells both in vitro and in vivo is becoming an ever more important means of elucidating pathways of molecular and…”
Get full text

Enoximone, a post-operative inodilator in patients following mitral valve operation: a prospective and controlled study by Hausen, B, von der Leyen, H, Vogelpohl, J, Dresler, C, Heublein, B, Haverich, A

“…Inotropic support is often required for post-operative management of patients following mitral valve operation. The use of positive inotropes is limited by…”
Get more information

Gene inhibition and gene augmentation for the treatment of vascular proliferative disorders by von der Leyen, H E, Mann, M J, Dzau, V J

“…Gene therapy is emerging as a potential strategy for the treatment of vasculoproliferative diseases such as restenosis after angioplasty, vascular bypass graft…”
Get more information